{
    "2020-08-02": [
        [
            {
                "time": "2020-08-02",
                "original_text": "上周电子和医药行业涨幅领先——华泰金工FOF投资周报20200802",
                "features": {
                    "keywords": [
                        "电子",
                        "医药",
                        "涨幅",
                        "华泰金工",
                        "FOF投资"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "电子",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "誉衡药业转型艰难",
                "features": {
                    "keywords": [
                        "誉衡药业",
                        "转型",
                        "艰难"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "信迪利二季度5亿 上半年销售接近O药全年",
                "features": {
                    "keywords": [
                        "信迪利",
                        "二季度",
                        "销售",
                        "O药"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药营收、净利增速下滑 股权激励计划能否奏效？ 盈利能力下降",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "营收",
                        "净利",
                        "增速下滑",
                        "股权激励",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药净赚26亿背后:疫情下仍花35亿开会, 行贿丑闻致子公司清算 其他违规处罚",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "净赚26亿",
                        "疫情",
                        "开会",
                        "行贿丑闻",
                        "子公司清算",
                        "违规处罚"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药(600276)：中报业绩稳定增长 股权激励保障长期动力",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "中报业绩",
                        "稳定增长",
                        "股权激励",
                        "长期动力"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业每周医览药闻：疫苗依然是解决新冠疫情的最根本方法",
                "features": {
                    "keywords": [
                        "医药行业",
                        "疫苗",
                        "新冠疫情",
                        "根本方法"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}